Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19210719 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | May 2025 | January 2026 | Allow | 8 | 2 | 0 | Yes | No |
| 18818363 | TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDS | August 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18659232 | PUTRESCINE TOPICAL BARRIER FORMULATION | May 2024 | July 2025 | Allow | 14 | 1 | 0 | No | No |
| 18624804 | Personal Care Formulations | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18435678 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | February 2024 | March 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18406793 | Cardiovascular Prostheses | January 2024 | December 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18397626 | PROCESS OF MAKING NANOEMULSION | December 2023 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18525209 | MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS | November 2023 | December 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18386560 | 2-BENZO-[3,4-B] QUINOLINO-{B,G]INDENO [1',2':3,4] FLUORENO-[1,2-D] OXONINE-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18386579 | 3-(4-BROMOPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | August 2024 | Allow | 9 | 2 | 1 | No | No |
| 18383999 | OCULAR INFLAMMATION TREATMENT WITH STABILIZED DEXAMETHASONE | October 2023 | February 2026 | Abandon | 27 | 4 | 0 | No | No |
| 18493990 | COSMETIC COMPOSITIONS, KITS THEREOF, AND METHODS FOR MAKING AND USING THE SAME | October 2023 | June 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18282627 | METHOD OF TREATING INFECTED AND NONINFECTED BURN WOUNDS | September 2023 | February 2026 | Abandon | 29 | 1 | 0 | No | No |
| 18547346 | HAIR COSMETIC | August 2023 | March 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18231599 | Hair and Scalp Compositions and Related Treatment Methods | August 2023 | February 2026 | Abandon | 30 | 1 | 0 | No | No |
| 18365724 | TRANSDERMAL DELIVERY SYSTEM INCLUDING AN INTERFACE MEDIATOR | August 2023 | June 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18275718 | SPHERULITE COMPOSITIONS | August 2023 | March 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18274638 | WATER-IN-OIL MAKEUP COSMETIC COMPOSITION HAVING WATER RESISTANCE AND CLEANSING PROPERTIES | July 2023 | January 2026 | Allow | 30 | 1 | 0 | Yes | No |
| 18357927 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | July 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18345029 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | June 2023 | July 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18258256 | BIORESORBABLE SEALING POWDER | June 2023 | March 2026 | Allow | 33 | 1 | 0 | Yes | No |
| 18336431 | Silk-Based Moisturizer Compositions and Methods Thereof | June 2023 | June 2025 | Allow | 24 | 2 | 0 | No | No |
| 18334667 | PUTRESCINE TOPICAL BARRIER FORMULATION | June 2023 | July 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18327267 | TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERS | June 2023 | September 2024 | Allow | 16 | 3 | 0 | Yes | No |
| 18327278 | TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERS | June 2023 | September 2024 | Allow | 15 | 3 | 0 | Yes | No |
| 18124128 | COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERS | March 2023 | May 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18123268 | Fast Release Benzoic Acid In Feed | March 2023 | July 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18121576 | STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USE | March 2023 | July 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18177720 | POLYGLUTAMIC ACID COMPOSITIONS AND METHODS OF USING | March 2023 | April 2025 | Allow | 25 | 5 | 0 | Yes | No |
| 18115008 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS | February 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18112635 | SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS | February 2023 | February 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18171070 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | February 2023 | July 2024 | Allow | 17 | 4 | 0 | Yes | No |
| 18106684 | NATURAL POLYMER-BASED TISSUE ADHESIVE WITH HEALING-PROMOTING PROPERTIES | February 2023 | June 2024 | Allow | 16 | 2 | 0 | No | No |
| 18106501 | EDGED CATAPLASM AND MANUFACTURING PROCESS | February 2023 | February 2026 | Allow | 36 | 2 | 0 | Yes | No |
| 18007390 | BRIGHTENING COSMETIC COMPOSITION COMPRISING SODIUM PYRUVATE AS ACTIVE INGREDIENT | January 2023 | August 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18149804 | FOOD GRADE WHITENING AGENTS AND USES THEREOF | January 2023 | May 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18002859 | ANTISEPTIC COMPOSITIONS | December 2022 | March 2026 | Allow | 39 | 3 | 0 | Yes | No |
| 18009020 | ADHESIVE TRANSPARENT MULTIFUNCTIONAL WOUND-COVERING MATERIAL AND MANUFACTURING METHOD THEREOF | December 2022 | November 2025 | Abandon | 35 | 1 | 0 | No | No |
| 18007503 | Powder Coating Composition and Substrate Coated With Such Powder Coating Composition | December 2022 | January 2026 | Allow | 38 | 2 | 0 | No | No |
| 18056981 | TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDS | November 2022 | August 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18055494 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | November 2022 | November 2023 | Allow | 12 | 2 | 0 | No | No |
| 17984461 | Method To Improve The Health Of The Microbiome In A Human Gastrointestinal System And Multi-Chamber Probiotic Delivery Products Therefor | November 2022 | December 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17923076 | AN ANTIMICROBIAL COMPOSITION FOR TACKLING MALODOUR | November 2022 | May 2025 | Allow | 31 | 1 | 0 | No | No |
| 17922825 | HYALURONIC ACID-BASED HYDROGEL USING PEPTIDE CROSSLINKING AGENT, AND METHOD FOR PRODUCING SAME | November 2022 | February 2026 | Allow | 39 | 1 | 1 | No | No |
| 17970160 | KIT AND NEW METHOD OF TREATMENT FOR SKIN BASAL CELL AND SQUAMOUS CELL CARCINOMA | October 2022 | July 2023 | Allow | 8 | 1 | 1 | No | No |
| 17967470 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONS | October 2022 | July 2023 | Allow | 9 | 1 | 0 | No | No |
| 17962763 | COMPOSITIONS AND METHODS FOR TREATING HOT FLASHES | October 2022 | July 2025 | Allow | 34 | 3 | 0 | No | No |
| 17938613 | CBD SUNSCREEN FORMULATIONS AND USES THEREOF | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17995270 | MAKEUP APPLICATION METHOD | September 2022 | November 2025 | Allow | 37 | 2 | 0 | No | No |
| 17950387 | COMPOSITION FOR PROMOTING HAIR THICKENING, COMPOSITION FOR SUSTAINING GROWTH PHASE IN HAIR CYCLE AND COMPOSITION FOR PROMOTING VEGF PRODUCTION, COMPOSITION FOR PROMOTING TRANSITION FROM RESTING PHASE TO GROWTH PHASE IN HAIR CYCLE AND COMPOSITION FOR PROMOTING FGF7 PRODUCTION, AND COMPOSITION FOR PROMOTING HAIR CYCLE NORMALIZATION | September 2022 | August 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17939396 | POWDERED FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFEN | September 2022 | January 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17902646 | COSMETIC FORMULATION | September 2022 | March 2024 | Abandon | 19 | 3 | 0 | Yes | No |
| 17905616 | ORAL SOLID PREPARATIONS | September 2022 | September 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17799856 | ANTIMICROBIAL COMPOSITIONS | August 2022 | March 2026 | Allow | 43 | 2 | 0 | No | No |
| 17880586 | COSMETIC FORMULATION | August 2022 | October 2025 | Abandon | 38 | 2 | 0 | No | Yes |
| 17877005 | Water-soluble Unidirectional Moisture Transport Traditional Chinese Medicine Facial Mask and Preparation thereof | July 2022 | April 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17876700 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | July 2022 | August 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17795553 | COMPOSITIONS FOR HEMORRHOID TREATMENT | July 2022 | September 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17871111 | Personal Care Compositions Incorporating Natural Benefit Agents and Methods for the Same | July 2022 | May 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17759302 | MEDICAMENT COMPRISING A COMBINATION OF AMNIOTIC MEMBRANE AND UMBILICAL CORD BLOOD SERUM FOR WOUND HEALING | July 2022 | July 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17868480 | BIOCIDE COMPOSITION AND METHODS OF USE | July 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17866876 | DOSING REGIMENS AND METHODS FOR TREATING CANCER | July 2022 | August 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17758315 | ORAL SOLID CANNABINOID OIL COMPOSITION FOR TREATING GASTROINTESTINAL DISORDERS | July 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17854297 | CONTROLLED RELEASE CORE-SHELL PARTICLES AND SUSPENSIONS INCLUDING THE SAME | June 2022 | July 2025 | Allow | 37 | 3 | 1 | No | No |
| 17848981 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE INCLUDING PUER TEA EXTRACT | June 2022 | June 2025 | Allow | 36 | 4 | 0 | Yes | Yes |
| 17782088 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING THEREOF | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17831333 | TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOF | June 2022 | June 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17752915 | Antiseptic Wipes | May 2022 | December 2025 | Allow | 43 | 2 | 0 | No | No |
| 17751883 | COSMETIC PRODUCT COMPRISING A COSMETIC COMPOSITION CONTAINED IN AN APPLICATOR | May 2022 | June 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17746713 | COMPOSITION OF TANNIC ACID AND VITAMIN D AND METHODS OF USE | May 2022 | October 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17746555 | METHOD FOR WHITENING SKIN USING COMPOSITION FOR SKIN WHITENING | May 2022 | February 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17744685 | PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOF | May 2022 | November 2023 | Allow | 18 | 2 | 0 | No | No |
| 17743537 | WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTION | May 2022 | December 2023 | Allow | 19 | 2 | 0 | No | No |
| 17743529 | WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTION | May 2022 | January 2024 | Allow | 20 | 2 | 0 | No | No |
| 17743895 | Personal Care Formulations | May 2022 | December 2023 | Allow | 19 | 2 | 0 | No | No |
| 17739246 | Hydrogel-Fabric Composite For Cosmetic Applications | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17773497 | AQUEOUS OXIDIZING COMPOSITION COMPRISING AMINO ACIDS | April 2022 | August 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17755408 | OIL-IN-WATER TYPE COMPOSITION | April 2022 | June 2025 | Allow | 38 | 2 | 0 | No | No |
| 17732162 | COMPOSITION AND METHOD FOR ODOR CONTROL | April 2022 | August 2023 | Allow | 16 | 1 | 0 | No | No |
| 17730305 | STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USE | April 2022 | February 2023 | Allow | 10 | 2 | 0 | No | No |
| 17728522 | ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAME | April 2022 | March 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17770204 | PERSONAL CARE COMPOSITION COMPRISING A SILICON GLYCAN | April 2022 | July 2025 | Allow | 39 | 1 | 1 | No | No |
| 17717868 | Personal Care Composition | April 2022 | June 2023 | Allow | 14 | 1 | 0 | No | No |
| 17766487 | ORAL CARE COMPOSITION COMPRISING CUTTLEFISH BONE POWDER | April 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17763396 | A PUNICA GRANATUM EXTRACT AND ITS COSMETIC USES | March 2022 | October 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17763236 | TREATMENT OF SKIN DISORDERS WITH TOPICAL COMBINATION COMPOSITIONS COMPRISING TAPINAROF AND AN ADDITIONAL AHR ACTIVATOR | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17761792 | COMPOSITIONS AND METHODS FOR RESTORING OR INCREASING TISSUE PERFUSION | March 2022 | March 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17638713 | COMPOSITION, PROCESS AND KIT FOR SEMI-PERMANENT STRAIGHTENING AND CURLING OF KERATIN FIBERS | February 2022 | March 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17613448 | METHOD FOR STABILIZING HUMIDITY-SENSITIVE PHARMACEUTICAL SUBSTANCE AND STABILIZED PREPARATION THEREOF | February 2022 | February 2023 | Allow | 15 | 3 | 0 | Yes | No |
| 17674728 | PRODUCING ATP AND IMPROVING MITOCHONDRIAL FUNCTION IN A MAMMAL USING A POLY-OXYGENATED METAL HYDROXIDE | February 2022 | April 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17666577 | COMPOSITION FOR STIMULATING MUSCLE GROWTH, REPAIR, AND MAINTENANCE | February 2022 | April 2023 | Allow | 14 | 1 | 0 | No | No |
| 17666181 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONS | February 2022 | August 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17632959 | HIGH PERFORMANCE ANTIMICROBIAL COMPOSITION | February 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17586618 | DEFINED DOSE CANNABIS POD | January 2022 | May 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17627960 | Engineered biodegradable vascular bioprostheses and production process thereof | January 2022 | August 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17576675 | READY-TO-USE ESTHETIC COMPOSITIONS | January 2022 | March 2026 | Allow | 50 | 6 | 0 | Yes | Yes |
| 17576202 | USE OF NUTRITIONAL COMPOSITIONS HAVING A LOW PROTEIN AMOUNT | January 2022 | April 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17574511 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | January 2022 | April 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17626106 | COMPOSITION FOR EXTERNAL APPLICATION | January 2022 | August 2025 | Abandon | 43 | 4 | 0 | Yes | No |
| 17624797 | PREBIOTIC COSMETIC COMPOSITIONS AND METHODS FOR THE PREPARATION THEREOF | January 2022 | September 2025 | Abandon | 44 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANG, KYUNG SOOK.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHANG, KYUNG SOOK works in Art Unit 1613 and has examined 724 patent applications in our dataset. With an allowance rate of 61.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner CHANG, KYUNG SOOK's allowance rate of 61.3% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHANG, KYUNG SOOK receive 2.45 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHANG, KYUNG SOOK is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +40.0% benefit to allowance rate for applications examined by CHANG, KYUNG SOOK. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.1% of cases where such amendments are filed. This entry rate is in the 48% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 93.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 64.9% of appeals filed. This is in the 45% percentile among all examiners. Of these withdrawals, 62.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 56.1% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.